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Introduction:  
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication occurring in 1-3% 
of adult renal transplant recipients (RTR). We present a case series of 16 RTR who demonstrate a variety 
of PTLD manifestations. 
Results:  
63% of RTR received rATG induction and 38% Basiliximab. Maintenance immunosuppression 
post-transplantation was Prednisone, Tacrolimus, and Mycophenolate Mofetil.  
Average time from transplantation to PTLD diagnosis was 96.8 months (<1-20 years). PTLD 
localized to the GI tract (10), lymph nodes (9), CNS (4), bone marrow (3), lungs (2), mediastinum (2), 
skin (2), retroperitoneum (1), and native kidney/ureter (2). PTLD was EBV- (8), monomorphic (14), and 
of B-cell lineage (13). 3 RTR had T-cell PTLD. 
Immunosuppression was discontinued in all RTR at diagnosis except Prednisone. Treatment was 
chemotherapy alone or in combination with radiation, resection, or salvage therapy; complications 
included Tumor Lysis Syndrome and infections. 56% of RTR developed renal insufficiency. 
 5 RTR (31%) achieved complete remission with a functioning graft. PTLD mortality rate was 63%; 9 
RTR died with a functioning graft. Mortality with Basiliximab induction was 83% and 55% with rATG 
induction. T-cell PTLD had a 100% mortality while B-cell PTLD had a 54% mortality. EBV- PTLD had 
a higher mortality rate (88%) than EBV + (38%) PTLD. Patients died between <1-4 years after PTLD 
diagnosis. 
Conclusion:  
PTLD with T-cell characterization, EBV negative status, and bone marrow and lymph node 
involvement demonstrated an increased mortality rate. PTLD has a myriad of manifestations and should 
be considered as a differential diagnosis in patients presenting with post-transplant lesions. 
 
